Loading…
Relmada Therapeutics, Inc. is projected to rise to $6.66 by 2027, a +25% move from its current price of $5.31. RLMD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $5.14 | $5.31 | $5.49 | +0.08% |
| Aug 3 | $5.07 | $5.32 | $5.58 | +0.16% |
| Aug 4 | $5.02 | $5.32 | $5.64 | +0.24% |
| Aug 5 | $4.98 | $5.33 | $5.69 | +0.33% |
| Aug 6 | $4.95 | $5.33 | $5.74 | +0.41% |
| Aug 7 | $4.92 | $5.34 | $5.79 | +0.49% |
| Aug 8 | $4.89 | $5.34 | $5.83 | +0.57% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.89 | $5.34 | $5.83 | +0.57% |
| Week 2 | $4.74 | $5.37 | $6.08 | +1.15% |
| Week 3 | $4.64 | $5.40 | $6.29 | +1.73% |
| Week 4 | $4.55 | $5.43 | $6.48 | +2.31% |
| Week 5 | $4.49 | $5.46 | $6.66 | +2.90% |
| Week 6 | $4.43 | $5.50 | $6.82 | +3.48% |
| Week 7 | $4.38 | $5.53 | $6.98 | +4.08% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc. (RLMD) is a clinical-stage biotechnology company based in the United States. It trades at $5.00 per share and has a market capitalization of $550.13M, with a rank of 5321 among peers.
The forecast suggests a rising price path over the coming years, with the 2026 average around $5.00 and longer-term averages reaching $7.48 in 2030, $22.35 in 2040, and $40.08 in 2050, accompanied by increasing ROIs and bullish sentiment in the later years.
A major floor 28.8% below — a decisive break under it would weaken the trend.
The nearest floor, 5.8% below — buyers have tended to step in here.
The nearest ceiling, 31.5% above — a clean break opens room to run.
A major ceiling 48.0% above — clearing it would confirm fresh momentum.
Key RLMD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RLMD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.25 | Buy | $5.27 | Buy |
| MA 10 | $5.19 | Buy | $5.34 | Sell |
| MA 20 | $5.68 | Sell | $5.60 | Sell |
| MA 50 | $6.27 | Sell | $6.06 | Sell |
| MA 100 | $6.61 | Sell | $6.00 | Sell |
| MA 200 | $5.21 | Buy | $5.19 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.29 | Neutral |
| Stoch RSI (14) | 84.94 | Sell |
| CCI (20) | -44.38 | Neutral |
| Williams %R (14) | -74.38 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -14.49 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 25.62 | Neutral |
| TRIX (15) | -0.82 | Sell |
| Awesome (5,34) | -0.82 | Sell |
| Ultimate (7,14,28) | 56.00 | Neutral |
| Momentum (10) | 0.07 | Buy |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 5.29 | Buy |
| ADX (14) | 23.05 | Sell |
| ATR (14) | 0.16 | Info |
Near-term technical picture shows a bullish tilt. RSI(14) is 30, while the 50-day simple moving average is $6.62 and the 200-day simple moving average is $5.08. The current support is at $5.00 and resistance is at $6.98.
Over the last 30 days, the price traded in a range from $3.90 to $6.42, illustrating a notable but bounded near-term movement.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.55 | $5.31 | $7.93 | 0% | Neutral | |
| $5.20 | $6.66 | $9.07 | +25% | Bullish | |
| $5.77 | $7.65 | $10.90 | +44% | Bullish | |
| $6.09 | $8.32 | $12.26 | +57% | Bullish | |
| $6.57 | $9.21 | $13.97 | +73% | Bullish | |
| $7.56 | $10.84 | $16.86 | +104% | Bullish | |
| $9.15 | $13.42 | $21.35 | +153% | Bullish | |
| $10.88 | $16.29 | $26.44 | +207% | Bullish | |
| $11.38 | $17.39 | $28.75 | +228% | Bullish | |
| $11.57 | $18.03 | $30.32 | +240% | Bullish | |
| $17.70 | $30.12 | $54.37 | +467% | Bullish | |
| $29.39 | $58.47 | $116.92 | +10.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.55 | $5.31 | $6.77 | +0.00% |
| September 2026 | $4.78 | $5.70 | $7.00 | +7.31% |
| October 2026 | $4.76 | $5.72 | $7.12 | +0.38% |
| November 2026 | $4.96 | $6.00 | $7.54 | +4.83% |
| December 2026 | $5.13 | $6.24 | $7.93 | +4.11% |
Click any year to see its month-by-month RLMD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Relmada Therapeutics, Inc.'s 2026 outlook centres on $5.31, within a $3.55 to $7.93 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, RLMD could reach as high as $9.07, with a base case around $6.66 and support toward $5.20 — roughly +25% from $5.31. Buyers look set to stay in control over this stretch.
Expect RLMD to range from $5.77 to $10.90 through 2028. The $7.65 average target implies a +44% move from current prices. That is up +15% on the projected 2027 average. Momentum favours further upside here.
The RLMD price prediction for 2029 points to an average of $8.32 (low $6.09, high $12.26) — a potential gain of +57% on today's $5.31. Buyers look set to stay in control over this stretch.
In 2030, RLMD is projected to trade between $6.57 and $13.97, averaging $9.21 — a potential gain of +73% from today's $5.31. That is up +11% on the projected 2029 average. Momentum favours further upside here.
Relmada Therapeutics, Inc.'s 2031 outlook centres on $10.84, within a $7.56 to $16.86 range. That is up +18% on the projected 2030 average. That marks a +104% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, RLMD could reach as high as $21.35, with a base case around $13.42 and support toward $9.15 — roughly +153% from $5.31. Momentum favours further upside here.
Expect RLMD to range from $10.88 to $26.44 through 2033. The $16.29 average target implies a +207% move from current prices. That is up +21% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The RLMD price prediction for 2034 points to an average of $17.39 (low $11.38, high $28.75) — a potential gain of +228% on today's $5.31. Momentum favours further upside here.
In 2035, RLMD is projected to trade between $11.57 and $30.32, averaging $18.03 — a potential gain of +240% from today's $5.31. That is up +4% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Relmada Therapeutics, Inc.'s 2040 outlook centres on $30.12, within a $17.70 to $54.37 range. That is up +67% on the projected 2035 average. That marks a +467% change versus current levels. Momentum favours further upside here.
By 2050, RLMD could reach as high as $116.92, with a base case around $58.47 and support toward $29.39 — roughly +10.0x from $5.31. Buyers look set to stay in control over this stretch.
Investing $1,000 in RLMD today (≈ 188.323917 RLMD) could be worth
$11,011.35
+$10,011.35 (+1001%) by 2050 · US Dollar
Based on the average projected RLMD price of $58.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RLMDwould be worth at today's price.
$1,000 invested in RLMD on Jul 31, 2025 (≈ 1,607.717096 RLMD) would be worth
$8,536.98
+$7,536.98 (+753.7%) today · 8.54× · US Dollar
Based on a RLMD entry price of $0.622 vs. today's $5.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.18 | $1,025.1 | +2.5% |
| 1 month ago | $6.39 | $830.99 | -16.9% |
| 3 months ago | $7.64 | $695.03 | -30.5% |
| 6 months ago | $3.83 | $1,386.42 | +38.6% |
| 1 year ago | $0.622 | $8,536.98 | +753.7% |
| All time (5.0y) ago | $25.71 | $206.53 | -79.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RLMD forecast.
Our base-case forecast reaches $11.00 around 2032.
Implied market cap at $11.00: $1.15B
The multi-year forecast depicts a steady upward trajectory. In 2030, the average price is projected at $7.48 with a 49.5% ROI and bullish sentiment. The 2040 forecast shows an average of $22.35 with a 346.9% ROI and bullish sentiment, while 2050 carries an average of $40.08 with a 701.6% ROI and bullish sentiment.
Earlier years show gradual gains from 2026 through 2029: 2026 average $5.00 (ROI 0%), 2027 average $5.97 (ROI 19.5%), 2028 average $6.89 (ROI 37.8%), and 2029 average $7.08 (ROI 41.6%), all with neutral to bullish signals as the path to stronger upside unfolds. These estimates are not guarantees and actual results may vary.
Tap a question to reveal the answer.
2030 avg $7.48; min $5.17; max $11.71; ROI 49.5%; sentiment BULLISH.
The near-term forecasts show gradual gains from 2026 to 2029 (2026 avg $5.00, ROI 0%; 2027 avg $5.97, ROI 19.5%; 2028 avg $6.89, ROI 37.8%; 2029 avg $7.08, ROI 41.6%). The long-term outlook turns more bullish with 2030 avg $7.48 and ROI 49.5%.
Yes. The forecast lists a max of $10.75 in 2029, with higher maxima in subsequent years (e.g., 2032 max $17.46; 2033 max $21.86).
Current price $5.00; market cap $550.13M.
The 2040 average is $22.35 with ROI 346.9% and the 2050 average is $40.08 with ROI 701.6%, both indicating strong bullish potential over the long term.
Relmada Therapeutics, Inc. Community Discussion
0Share your Relmada Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.